VAM
KERX

Visium Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Visium Asset Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-65,000
Closed -$229K – 950
2015
Q3 		$229K Buy
65,000
+15,000
+30% +$100K ﹤0.01% 765
2015
Q2 		$499K Buy
50,000
+32,620
+188% +$350K 0.01% 647
2015
Q1 		$221K Buy
+17,380
New +$223K ﹤0.01% 906

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Visium Asset Management's KERX Position: Q4 2015 in Review

Visium Asset Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2015, closing a stake of 65,000 shares — an estimated $229K sold.

Visium Asset Management first reported a position in KERX in Q1 2015 and held it in 3 quarters. The position peaked at $499K in Q2 2015. 128 funds tracked by Wall St. Rank hold KERX as of Q4 2015.

  • Visium Asset Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2015 after selling out during the quarter.
  • Visium Asset Management sold 65,000 Keryx Biopharmaceuticals Inc shares in Q4 2015, an estimated $229K.
  • Visium Asset Management first reported a position in Keryx Biopharmaceuticals Inc in Q1 2015 and held it in 3 quarters.
  • Visium Asset Management's Keryx Biopharmaceuticals Inc position peaked at $499K in Q2 2015.
  • 128 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2015.

Based on Visium Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.